

John Dark  
Translational and Clinical Research Institute  
University of Newcastle upon Tyne  
Newcastle

Specialised Commissioning  
NHS England  
Skipton House  
80 London Road  
London  
SE1 6LH

cc: Dan.Harvey@nhsbt.nhs.uk  
studysupport.crns.london@nih.ac.uk  
SIGNET@nhsbt.nhs.uk

[england.speccommetcs@nhs.net](mailto:england.speccommetcs@nhs.net)

08 November 2021

Dear John Dark,

**IRAS: 288722- SIGNET: Statins for Improving Organ Outcome in Transplantation**

Under national assurance arrangements established in October 2018, it has been agreed that when potential excess treatment costs or savings relating to specialised care are identified in a study proposal, NHS England will have the opportunity to assure the costs proposed, consider whether expenditure might fall differentially across the country to inform regional budget setting and forecasting, and identify any issues or risks to be mitigated.

NHS England has now completed its review, based on the information received in the research proposal and the SoECAT submitted, of the proposed excess treatment costs of £44,122.

The completion of the financial assurance undertaken confirms the gross cost of the trial is £44,122 payable retrospectively as excess treatment costs at the rate of £16.97 per patient recruited. The gross figure takes into account payments that may already be made to commissioned providers under national tariff and NHS contract arrangements.

This information will be shared with NIHR and with NHS England's local commissioning teams / hubs. This letter may also be used by the principal investigator to demonstrate that the financial assurance of any additional costs or savings has been completed from a commissioning perspective.

I wish you every success with this clinical trial.

Yours sincerely,



**Ann Jarvis**  
Programme Director (Clinical Strategy)